Evidence map›Paper›PMID 32494878›Full record

ReviewCurrent gastroenterology reports2020

Stool-Based Tests for Colorectal Cancer Screening: Performance Benchmarks Lead to High Expected Efficacy.

Derek W Ebner, John B Kisiel

Open access · hybridAbstract readComparative StudyReview
In one paragraph

Review in Current gastroenterology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Colorectal cancer screening in the COVID-19 era.World journal of gastrointestinal oncology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Derek W EbnerDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
John B KisielDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Kisiel.john@mayo.edu.ORCID http://orcid.org/0000-0002-3840-5324
Mayo Clinic in Arizona · US

Funding

Multi-site Gastrointestinal Cancer Detection by Stool DNA MethylationR37CA214679 · NCI · MAYO CLINIC ROCHESTER · PI KISIEL, JOHN · 2018 to 2024
$2.8M
Multi-cancer Early DetectionR01CA214679 · NCI · MAYO CLINIC ROCHESTER · PI John Kisiel, Niloy Jewel Samadder · 2025 to 2026
$891k
NCI NIH HHS R01 CA214679NCI NIH HHS R37 CA214679
6 · The paper itself

Abstract

purpose of reviewParticipation goals for colorectal cancer (CRC) screening in the USA have not been met. Non-invasive screening strategies may improve CRC screening participation. We highlight recent literature on stool-based screening performance and expectations for emerging non-invasive screening tests. RECENT

findingsStool-based CRC screening detects screen-relevant colorectal neoplasia and outperforms a currently available plasma assay. Though modestly sensitive for CRC, adherence to annual fecal immunochemical testing (FIT) is sub-optimal. Multi-target stool DNA (MT-sDNA) has greater adherence, superior sensitivity for screen-relevant lesions (including those in the proximal colon and sessile serrated architecture), and equivalent specificity to FIT over a 3-year period. Stool-based CRC screening tests are anticipated to reduce the incidence and mortality of CRC through detection of early-stage cancers and high-risk polyps. These endpoints in performance will need to be met by emerging blood sample-based tests in order have meaningful impact in clinical practice.

Indexed as

BenchmarkingColonic PolypsColonoscopyColorectal NeoplasmsDNA, NeoplasmEarly Detection of CancerFecesGuideline AdherenceHumansImmunochemistryMass ScreeningOccult BloodPatient ComplianceSeptinsDNA, NeoplasmSEPTIN9 protein, humanSeptinsColonic neoplasms/preventionFecal immunochemical testLiquid biopsyMulti-target stool DNA testOccult blood/methods

Identifiers

PMID32494878
PMCPMC7271040
OpenAlexW3028817391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.